Purpose: We previously reported that ADAMTS-7 and ADAMTS-12, two members of ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) family, sharing the similar domain organization in the family, degraded COMP in vitro and were significantly induced in the cartilage and synovium of arthritic patients (Liu, et al, FASEB J. 2006; 20(7) : 988 and Liu, et al, J. Biol. Chem. 2006; 281(23) :15800). The purpose of this study was to determine 1) whether cleavage activity of ADAMTS-7 and -12 of COMP are associated with COMP degradation in osteoarthritis; 2) whether a2M is a novel substrate for ADAMTS-7 and -12; and 3) whether a2M inhibits ADAMTS-7 or -12 cleavage of COMP. Methods: In vitro digestion assay of COMP by ADAMTS-7 and ADAMTS-12; COMP degradation analyses in the cartilage of OA patients; COMP degradation assay from the organ culturing system in the presence of TNF-α with or without blocking antibodies; COMP degradation assay from human chondrocytes in which expressions of ADAMTS-7 or/and -12 were knock-down by specific siRNA; Digestion of alpha-2-macroglobulin (a2M) by ADAMTS-7 and -12 in vitro as well as the inhibition assays of α2M on ADAMTS-7 or -12 digestion of COMP. Results: The size of the COMP fragments produced by either ADAMTS-7 or ADAMTS-12 is similar to that of COMPdegradative fragments seen in OA patients; antibody blocking assay indicated that specific antibodies against ADAMTS-7 or ADAMTS-12 dramatically inhibits TNF-α-induced COMP degradation in the cultured cartilage explants; and suppression of ADAMTS-7 or ADAMTS-12 expression using siRNA silencing approach in the human chondrocytes also markedly prevents TNFα-induced COMP degradation. Both ADAMTS-7 and ADAMTS-12 metalloproteinases were able to cleave α 2 M in a dosedependent manner, which gave rise to the cleavage products with the molecular weights of 180 and 105 kDa respectively. Further, α 2 M inhibits both ADAMTS-7-and ADAMTS-12-mediated COMP degradation in a does-dependent manner. Conclusions: Our observation demonstrated the importance of COMP degradation by ADAMTS-7 and ADAMTS-12 in vivo; furthermore, we revealed that α 2 -Macroglobulin (α 2 M) is a novel substrate for ADAMTS-7 and ADAMTS-12. More significantly, α 2 M represents the first endogenous inhibitor of ADAMTS-7 and ADAMTS-12. Purpose: The discovery that chondrocytes, synoviocytes and dermal fibroblasts all produce a neutral active hyaluronidase similar to the sperm or testicular hyaluronidase PH-20 might provide new and important insights into mechanisms implicated during embryogenesis and during the development of skin and joint disorders. Therefore, we herein assessed the levels of PH-20 expression in human normal and osteoarthritic articular cartilage.
EVIDENCE THAT THE NEUTRAL ACTIVE HYALURONIDASE PH-20 CONTRIBUTES TO THE BREAKDOWN OF CARTILAGE MATRIX IN HUMAN KNEE OSTEOARTHRITIS
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Methods: Human knee articular cartilage with its subchondral bone was either obtained from a tissue bank or sampled during surgery for total knee joint replacement. Tissues were immediately processed for in situ hybridization and immunohistology. Fluorescence intensity was semi-quantified and values obtained for PH-20 were normalized by those obtained for cell DNA by using DAPI. The severity of the OA disease process was evaluated by using the histologic-histochemical grading system devised by Mankin. Results: In normal cartilage PH-20 mRNA and PH-20 protein were only detected in few chondrocytes of the superficial cartilage layer as well as in few osteoclasts and osteoblasts of the subchondral bone. As the severity of the OA disease process increased, chondrocytes of middle and deeper cartilage layers expressed the enzyme both at the mRNA and protein levels. Scores of the Mankin's scale correlated significantly with the level of PH-20 expression as assessed by fluorescence intensity. The enzyme was also detected outside cartilage cells mostly in areas exhibiting erosions and in areas surrounding clefts. In specimens with moderate to severe OA lesions, one could also detect the enzyme signal in subchondral bone and in some connective tissues cells filling up the spaces between bone trabeculae. Conclusions: Our data provide evidence that the PH-20 produced by chondrocytes might be implicated in the degradation of cartilage matrix during OA. Indeed, the enzyme not only degrades hyaluronan, the backbone of aggrecan aggrecates and a backbone of the pericullar matrix, but also chondroitin sulfate chains. Our data also suggest that, in OA, other cell lines present in subchondral bone areas might contribute to the local production of PH-20. Purpose: Depletion of aggrecan is one of the earliest changes observed in osteoarthritis (OA). Aggrecan is a chondroitin sulfate and keratan sulfate-bearing proteoglycan. Aggrecan cleavage by Aggrecanase results in the release of a large sulfated glycosaminoglycan (sGAG)-containing aggrecan fragments which diffuse out of the cartilage matrix. Inhibiting Aggrecanase activity is an attractive therapeutic target. The purpose of this study was to understand the effects of a selective Aggrecanase inhibitor on the fate of existing and newly synthesized proteoglycan in human osteoarthritic articular cartilage. Methods: Human cartilage from total knee replacements harvested within 3 hours of surgery was used for this study (n=3 donors). Harvested cartilage was maintained in culture in the presence or absence of a selective Aggrecanase inhibitor. Total proteoglycan content of conditioned media or cartilage matrix was measured as sGAG by a colorimetric assay with dimethylmethylene blue. Aggrecan released from the cartilage was further characterized using a monoclonal antibody (BC-3) that recognizes the neoepitope generated by Aggrecanase-mediated cleavage of aggrecan. Articular cartilage was cultured in the presence of [ 35 S]sulfate to enable localization and characterization of newly synthesized aggrecan. Results: Human osteoarthritic articular cartilage from joints undergoing total knee replacement demonstrated significant, ongoing aggrecanase activity evidenced by release of aggrecan cleaved at the "aggrecanase cleavage site" (G373-374A). Incubation in the presence of the selective Aggrecanase inhibitor reduced total proteoglycan loss. Cleavage of newly synthesized aggrecan was a significant component of the degradative process, and Aggrecanase inhibition resulted in increased incorporation of new proteoglycan into the cartilage matrix. Conclusions: Aggrecanase activity is a characteristic of human osteoarthritis throughout the disease process. Inhibition of Aggrecanase activity reduced release of aggrecan degradation products from the articular cartilage matrix. Because newly synthesized aggrecan appeared to be especially susceptible to degradation by Aggrecanases, selective Aggrecanase inhibition resulted in a net increase in proteoglycan incorporation into the matrix of human osteoarthritic cartilage. These results indicate that inhibition of Aggrecanases will reduce aggrecan degradation in human osteoarthritric articular cartilage throughout the disease process, and may also result in a net increase in extracellular matrix proteoglycan. 
SELECTIVE INHIBITION OF AGGRECANASE PREVENTS AGGRECAN DEGRADATION AND PROMOTES INCORPORATION OF NEWLY SYNTHESIZED AGGRECAN INTO THE EXTRACELLULAR MATRIX OF HUMAN
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